CYCLOMEDICA AUSTRALIA PTY LTD

Cyclomedica is a globally recognized leader in nuclear medicine and molecular imaging, specializing in functional lung imaging. Operating under Cyclopharm Limited since 1984, the company pioneered Technegas®, a radioactive carbon nanoparticle-based diagnostic agent approved for clinical use in Australia in 1986 and now distributed across 65 countries. With over 4.7 million patient procedures delivered, Technegas® is the flagship product for advanced pulmonary diagnostics. The company's core competency encompasses nuclear pulmonology imaging with multiple product variations including Pertechnegas® and Galligas, supported by the TechnegasPlus generator. Cyclomedica actively pursues expanded clinical indications beyond pulmonary embolism, including COPD, asthma, chronic thromboembolic pulmonary hypertension, pre-operative quantification, radiotherapy planning, and COVID-19 complications. The organization maintains a strong regulatory compliance posture and operates a global network of regional offices and distributors to support healthcare providers in respiratory patient management and clinical outcomes improvement.